1122090-50-9

Basic information

• Product Name: Ethyl 6-chloro-4-methylpyridine-2-carboxylate
• Synonyms: Ethyl 6-chloro-4-methylpicolinate;6-Chloro-4-methyl-2-pyridinecarboxylic acid ethyl ester;Ethyl 6-chloro-4-methylpyridine-2-carboxylate;Methyl 6-chloro-4-Methylpyridine-2-carboxylate
• CAS NO: 1122090-50-9
• Molecular Formula: C9H10ClNO2
• Molecular Weight: 199.6342
• Product Categories: Heterocycle-Pyridine series
• Mol File: 1122090-50-9.mol

Chemical Properties

• Boiling Point: 311.538 °C at 760 mmHg
• Flash Point: 142.213 °C
• Appearance: /
• Density: 1.208 g/cm³
• CAS DataBase Reference: Ethyl 6-chloro-4-methylpyridine-2-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: Ethyl 6-chloro-4-methylpyridine-2-carboxylate(1122090-50-9)
• EPA Substance Registry System: Ethyl 6-chloro-4-methylpyridine-2-carboxylate(1122090-50-9)

Safety Data

• Hazardous Substances Data: 1122090-50-9(Hazardous Substances Data)

Usage

Uses

Used in Chemical Research:
Ethyl 6-chloro-4-methylpyridine-2-carboxylate is used as a research compound for the synthesis and development of new chemical entities. Its unique structure with a chlorine atom and a methyl group on the pyridine ring makes it a valuable intermediate in the preparation of various organic molecules and pharmaceuticals.
Used in Pharmaceutical Industry:
Ethyl 6-chloro-4-methylpyridine-2-carboxylate is used as a building block in the synthesis of pharmaceutical compounds. Its presence in the molecular structure can contribute to the development of new drugs with potential therapeutic applications, such as in the treatment of various diseases and disorders.
Used in Material Science:
Ethyl 6-chloro-4-methylpyridine-2-carboxylate is used as a component in the development of new materials with specific properties. Its incorporation into the molecular structure of materials can lead to the creation of novel compounds with unique characteristics, such as improved stability, reactivity, or selectivity in various chemical processes.

Upstream product

• 324028-95-7 6-chloro-4-methylpyridine-2-carboxylic acid 
• 64-17-5 ethanol 
• 1122090-46-3 6-chloro-4-methyl-2-vinylpyridine 
• 1122090-48-5 potassium 6-chloro-4-methylpyridine-2-carboxylic acid 

Downstream Products

• 1227606-30-5 2-chloro-6-(chloromethyl)-4-methyl-pyridine 

Relevant articles and documents

3-SUBSTITUTED PIPERIDINE COMPOUNDS FOR CBL-B INHIBITION, AND USE OF A CBL-B INHIBITOR IN COMBINATION WITH A CANCER VACCINE AND/OR ONCOLYTIC VIRUS

Compounds, compositions, and methods for use in inhibiting the E3 enzyme Cbl-b in the ubiquitin proteasome pathway are disclosed. The compounds, compositions, and methods can be used to modulate the immune system, to treat diseases amenable to immune system modulation, and for treatment of cells in vivo, in vitro, or ex vivo. Also disclosed are pharmaceutical compositions comprising a Cbl-b inhibitor and a cancer vaccine, as well as methods for treating cancer using a Cbl-b inhibitor and a cancer vaccine; and pharmaceutical compositions comprising a Cbl-b inhibitor and an oncolytic virus, as well as methods for treating cancer using a Cbl-b inhibitor and an oncolytic virus.

Novel S1P1 receptor agonists - Part 3: From thiophenes to pyridines

In preceding communications we summarized our medicinal chemistry efforts leading to the identification of potent, selective, and orally active S1P 1 agonists such as the thiophene derivative 1. As a continuation of these efforts, we replaced the thiophene in 1 by a 2-, 3-, or 4-pyridine and obtained less lipophilic, potent, and selective S1P1 agonists (e.g., 2) efficiently reducing blood lymphocyte count in the rat. Structural features influencing the compounds' receptor affinity profile and pharmacokinetics are discussed. In addition, the ability to penetrate brain tissue has been studied for several compounds. As a typical example for these pyridine based S1P 1 agonists, compound 53 showed EC50 values of 0.6 and 352 nM for the S1P1 and S1P3 receptor, respectively, displayed favorable PK properties, and penetrated well into brain tissue. In the rat, compound 53 maximally reduced the blood lymphocyte count for at least 24 h after oral dosing of 3 mg/kg.

NOVEL PYRIMIDINE-PYRIDINE DERIVATIVES

The invention relates to novel pyrimidine-pyridine derivatives, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents.

PYRIDINE DERIVATIVES AS S1P1/EDG1 RECEPTOR MODULATORS

The invention relates to novel pyridine derivatives of formula (D, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents. Formula (I) wherein A represents and the other substituents are as defined in the claims.

PYRIDIN-2-YL DERIVATIVES AS IMMUNOMODULATING AGENTS

The invention relates to pyridine derivatives of Formula (I), wherein A, R1, R2, R3, R4, R5, R6 and R7 are as described in the description, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents.

NOVEL PYRIMIDINE-PYRIDINE DERIVATIVES

The invention relates to novel pyrimidine-pyridine derivatives, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents. Formula I.

PYRIDINE DERIVATIVES AS S1P1/EDG1 RECEPTOR MODULATORS

The invention relates to novel pyridine derivatives of formula (D, their preparation and their use as pharmaceutically active compounds. Said compounds particularly act as immunomodulating agents. Formula (I) wherein A represents and the other substituants are as defined in the claims.